Trade Mark Journal No.2026/014 3 April 2026

UK00004355456 16 March 2026 (42)

SYNTASE

International priority date claimed: 30 September 2025 (United States of America) (99421485)

Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy; Research in the field of gene editing technology; Providing a gene editing platform for others to conduct pharmaceutical research and development in the field of in vivo gene editing therapy.

CRISPR Therapeutics AG

Representative: HGF Limited